Company Overview - Recently, the legal representative of Dirui Medical Technology Co., Ltd. has changed from Wang Xueming to Lang Tao [1] - Dirui Medical was established in 1994 and is located in Changchun City, primarily engaged in the manufacturing of specialized equipment [1] - The company has a registered capital of 2,727,001,610 RMB and a paid-in capital of 1,533,500,000 RMB [1] Investment and Intellectual Property - Dirui Medical has invested in 20 enterprises and participated in 1,406 bidding projects [1] - The company holds 23 trademark registrations and 540 patent registrations [1] - Additionally, Dirui Medical possesses 2,211 administrative licenses [1]

Core Viewpoint - Recently, the company completed the necessary business registration changes and obtained a new business license issued by the Changchun Market Supervision Administration, with the legal representative now being Lang Tao [2] Group 1 - The company has successfully completed the relevant business registration changes [2] - The new business license was issued by the Changchun Market Supervision Administration [2] - The legal representative of the company has changed to Lang Tao [2]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-034 2025 年 08 月 20 日 近日，公司完成了相关的工商变更登记工作，并取得由长春市市场监督管理 局长春新区分局换发的《营业执照》。公司法定代表人变更为郎涛。 除上述变更外，公司营业执照记载的其他事项未发生变化。 特此公告。 迪瑞医疗科技股份有限公司董事会 迪瑞医疗科技股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于2025年08月07日召开了 2025年第一次临时股东大会审议通过了《关于变更公司董事的议案》。同日，公 司召开了第六届董事会第三次临时会议审议通过了《关于选举公司第六届董事会 董事长的议案》《关于变更高级管理人员的议案》。具体内容详见公司披露于巨 潮资讯网（www.cninfo.com.cn）上的相关公告。 ...

Company Overview - Dirui Medical's closing price on August 14 was 14.89 yuan, down 2.68%, with a rolling PE ratio of 113.42 times and a total market value of 4.061 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.76 times and a median of 39.14 times, placing Dirui Medical at the 106th position in the industry ranking [1] - As of March 31, 2025, Dirui Medical had 17,877 shareholders, a decrease of 209 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Dirui Medical specializes in the research, development, production, marketing, and service of medical testing instruments and related reagents [1] - The main products include urine analysis, biochemical analysis, chemiluminescence immunoassay, gynecological secretion analysis, blood cell analysis, coagulation analysis, and overall laboratory solutions [1] - The company holds 213 patents, including 136 invention patents, and has obtained 96 software copyrights [1] Financial Performance - In the latest quarterly report for Q1 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Dirui Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of August 8, Dirui Medical's stock closed at 15.47 yuan, with a PE ratio of 117.84, marking a new low in 91 days, and a total market capitalization of 4.219 billion yuan [1] - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, positioning Dirui Medical at 107th place within the industry [1][2] Group 2 - Dirui Medical's main business involves the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, and blood cell analysis [1] - The company holds 213 patents, including 136 invention patents and 96 software copyrights [1] - In the first quarter of 2025, Dirui Medical reported a revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13%, with a gross margin of 42.78% [1]

从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三人年薪分别为284万元、171.11万元、136.67 万元。 从薪酬变动幅度看（仅统计任职两年以上董秘薪资数据），迪瑞医疗的安国柱2024年薪酬降幅最大，同比降幅达25.82%；九强生物的王建民薪酬增幅最大，同比涨幅达172.86%。 责任编辑：公司观察 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪7 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比为1 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比 为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年龄33岁，为 爱威科技的袁绘杰；最年轻的女董秘年龄为32岁，为易瑞生物的李文天。 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三 ...

（文章来源：证券日报） 证券日报网讯 8月7日晚间，迪瑞医疗发布公告称，公司2025年第一次临时股东大会审议通过了《关于 变更公司董事的议案》《关于公司续聘2025年度审计机构的议案》。 ...

Core Viewpoint - The company announced the election of Mr. Guo Ting as the chairman of the sixth board of directors, effective immediately upon approval by the board [1] Summary by Categories - **Company Leadership** - Mr. Guo Ting has been elected as the chairman of the sixth board of directors [1]

Group 1 - The company, Dirui Medical, announced the appointment of Mr. Lang Tao as the new General Manager, making him the legal representative of the company [2] - Mr. Sun Bin has been appointed as the Deputy General Manager of the company [2] - For the fiscal year 2024, the company's revenue composition is as follows: 99.52% from medical devices and 0.48% from other businesses [2]